Disease: Stomach Carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.060 Biomarker disease BEFREE VEGF-C depletion suppressed RhoGDI2-induced gastric cancer metastasis and sensitized RhoGDI2-overexpressing cells to cisplatin-induced apoptosis in vitro and in vivo. 24585459 2014
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.060 Biomarker disease BEFREE These results indicate that RhoGDI2 plays a critical role in tumor progression in gastric cancer through induction of EMT. 24721928 2014
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.060 Biomarker disease BEFREE Rho GDP dissociation inhibitor 2 (RhoGDI2) promotes tumor growth and malignant progression and enhances chemoresistance of gastric cancer. 24185104 2013
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.060 Biomarker disease BEFREE Recently, we suggested that RhoGDI2 could promote tumor growth and malignant progression in gastric cancer. 21752536 2011
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.060 Biomarker disease BEFREE PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer. 21986528 2011
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.060 Biomarker disease BEFREE Our findings indicate that RhoGDI2 is involved in gastric tumor growth and metastasis, and that RhoGDI2 may be a useful marker for tumor progression of human gastric cancer. 19351766 2009